Danaher (DHR) Stock Looks Reasonable On Cash Flow Yet Stretched On Earnings
Danaher stock has been roughly flat over the past year, while the valuation picture is mixed. A Discounted Cash Flow (DCF) estimate points to a fair price, but broader checks and market multiples suggest the shares are not especially cheap.
- Over the past 5 years, Danaher has delivered a total return that declined 23.5%, which frames the current valuation debate against a weak longer term share price record.
- Progress in areas like CRISPR off target analytics and AI enabled digital pathology can support long run cash flow expectations, but slower or uneven recovery in key life sciences markets may limit how much investors are willing to pay for that growth.
- Danaher scores 2 out of 6 on Simply Wall St's broader valuation checks, which leans expensive rather than a clear bargain overall. This is the case even if the intrinsic value looks roughly in line with the market price at about US$211.50 today.
The issue now is whether Danaher's current price fairly reflects its cash flow potential or asks investors to accept limited upside after a lacklustre 5 year return profile.
Find out why Danaher's 0.8% return over the last year is lagging behind its peers.
Is Danaher Fairly Priced on Cash Flow?
The Discounted Cash Flow model estimates what Danaher might be worth based on the cash it can generate for shareholders. Danaher produced last twelve month free cash flow of about $5.3b, and the model assumes these cash flows are growing from here rather than shrinking. On that basis, the 2 Stage Free Cash Flow to Equity approach points to an estimated intrinsic value of about $229 per share.
That compares to a current market price near $211, which implies the stock screens roughly 7.6% undervalued on this view. The UNCOVERseq progress at Integrated DNA Technologies, which sharpens Danaher’s position in CRISPR off target analytics, helps explain why the model builds in ongoing cash generation from high value life sciences tools. The DCF work suggests Danaher appears close to fairly valued, with the current price sitting only modestly below the estimated intrinsic value.
Danaher is fairly valued according to our Discounted Cash Flow (DCF), but this can change at a moment's notice. Track the value in your watchlist or portfolio and be alerted on when to act.
Has Danaher Run Too Far on Earnings?
The P/E ratio is a useful way to see what you are paying for each dollar of Danaher earnings today. Danaher currently trades on a P/E of about 37.3x, which is very close to the broader life sciences industry average near 37.7x.
However, Simply Wall St’s fair P/E for Danaher is estimated at about 28.9x, which is lower than both the current multiple and the peer average of roughly 31.2x. That indicates the stock trades at a valuation premium to what the model implies given its size, margins and risk profile. The gap between the current 37.3x and the fair 28.9x shows that the market is already pricing in a lot of optimism around Danaher, despite its less convincing 5 year share price record.
On this P/E measure, Danaher stock appears overvalued relative to what the fair multiple suggests.
See what the numbers say about this price — find out in our valuation breakdown.
The Danaher Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where the Danaher valuation puzzle leaves off by spelling out which assumptions on growth, margins and earnings would need to play out for the stock to be worth materially more or less than today's price. Each narrative ties its number to a clear view of where Danaher's growth, profitability and risks might head next, which you can revisit as new data and company updates come through.
Share a narrative on Danaher that includes your own estimates for the stock and sets out a clear view on whether developments like UNCOVERseq and AI in digital pathology support today's price. Add your voice to the Simply Wall St community so you can track how your thesis holds up as new results and research updates arrive.
Do you think there's more to the story for Danaher? Head over to our Community to see what others are saying!
The Bottom Line
The Discounted Cash Flow (DCF) work suggests Danaher is close to intrinsic value with only a modest implied discount, while the P/E view points to the stock as overvalued relative to its fair multiple. That split reflects a model that focuses on long run cash generation versus a market that is already pricing in strong expectations on earnings and sentiment. Broader checks lean weak, so the small DCF discount does not on its own signal a clear bargain. The real swing factor from here is whether Danaher can convert its life sciences pipeline into durable cash flows that justify the current earnings multiple.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com